Patritumab — drug · CancerIndex

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	6	—	—	2010-09
Malignant Lung Neoplasm	Phase3	Phase 3	1	2	—	—	2010-09
Malignant Breast Neoplasm	Phase2	Phase 2	0	1	—	—	2011-11

Computedclinicaltrials

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRG1 Expression1
Patritumab	Lung Non-Small Cell Carcinoma

Clinical trials

Trials with this intervention (6)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–6 of 6 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01211483	Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer	completed	Phase 1 / Phase 2	222	Daiichi SankyoINDUSTRY	13	Jun 16, 2021	clinicaltrials
NCT02633800	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )	terminated